Circulating high-sensitivity troponin T and microRNAs as markers of myocardial damage during childhood leukaemia treatment

Cheung, Yiu‐fai; Li, Vivian Wing‐yi; Lai, Clare Tik-man; Shin, Vivian Y.; Keung, Wendy; Cheuk, Dkl; Kwong, Ava; Li, Ronald Adolphus; Chan, Godfrey Chi‐Fung

doi:10.1038/s41390-020-1049-5

Cited by 19 publications

(18 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Heart‐enriched miRNAs including, miR‐208a were significantly increased in the culture medium upon exposure of human induced pluripotent stem cell‐derived cardiomyocytes to doxorubicin. However, miR‐208a failed to be detected in 69–90% of patients with pediatric leukemic during anthracycline‐based therapy 122 . Moreover, in a previous study, administration of a single high dose of doxorubicin to rats did not significantly affect circulating levels of miR‐208a or cardiac troponins (cTnI and cTnT) 120 .…”

Section: Roles Of Mir‐208a In Reverse Cardio‐oncologymentioning

confidence: 94%

Emerging roles of microRNA‐208a in cardiology and reverse cardio‐oncology

Xiang

Chen

et al. 2021

Medicinal Research Reviews

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs) and cancer, which are the leading causes of mortality globally, have been viewed as two distinct diseases. However, the fact that cancer and CVDs may coincide has been noted by cardiologists when taking care of patients with CVDs caused by cancer chemotherapy; this entity is designated cardio‐oncology. More recently, patients with CVDs have also been found to have increased risk of cancers, termed reverse cardio‐oncology. Although reverse cardio‐oncology has been highlighted as an important disease state in recent studies, how the diseased heart affects cancer and the potential mediators of the crosstalk between CVDs and cancer are largely unknown. Here, we focus on the roles of cardiac‐specific microRNA‐208a (miR‐208a) in cardiac and cancer biology and explore its essential roles in reverse cardio‐oncology. Accumulating evidence has shown that within the heart, increased miR‐208a promotes myocardial injury, arrhythmia, cardiac remodeling, and dysfunction and that secreted miR‐208a in the circulation may have novel roles in promoting tumor proliferation and invasion. This review, therefore, provides insights into the novel roles of miR‐208a in reverse cardio‐oncology and strategies to prevent secondary carcinogenesis in patients with early‐ or late‐stage heart failure.

show abstract

Section: Roles Of Mir‐208a In Reverse Cardio‐oncologymentioning

confidence: 94%

Emerging roles of microRNA‐208a in cardiology and reverse cardio‐oncology

Xiang

Chen

et al. 2021

Medicinal Research Reviews

View full text Add to dashboard Cite

show abstract

“…A study by Nishimura et al [ 109 ] treated rats with DOX (30 mg/kg) and collected blood samples after 2, 4, 8, and 24 h. Studies showed that miR-1 levels in the venous blood of rats treated with DOX for 8 h were elevated ( p < 0.01). Another study [ 110 ] treated in vitro human pluripotent stem cells (hPSC)-ventricular cardiomyocytes with DOX (1 μmol/L) for 48h, which resulted in a dose and time-dependent upregulation of miR-1.…”

Section: Mirna As a Biomarker Of Dicmentioning

confidence: 99%

MicroRNA in the Diagnosis and Treatment of Doxorubicin-Induced Cardiotoxicity

Kuang

Tan

et al. 2023

Biomolecules

View full text Add to dashboard Cite

Doxorubicin (DOX), a broad-spectrum chemotherapy drug, is widely applied to the treatment of cancer; however, DOX-induced cardiotoxicity (DIC) limits its clinical therapeutic utility. However, it is difficult to monitor and detect DIC at an early stage using conventional detection methods. Thus, sensitive, accurate, and specific methods of diagnosis and treatment are important in clinical practice. MicroRNAs (miRNAs) belong to non-coding RNAs (ncRNAs) and are stable and easy to detect. Moreover, miRNAs are expected to become biomarkers and therapeutic targets for DIC; thus, there are currently many studies focusing on the role of miRNAs in DIC. In this review, we list the prominent studies on the diagnosis and treatment of miRNAs in DIC, explore the feasibility and difficulties of using miRNAs as diagnostic biomarkers and therapeutic targets, and provide recommendations for future research.

show abstract

“…During the past few years, although chemotherapies have improved long-term survival rates, there is, unfortunately, an additional increased risk of cardiac complications because of underlying long-term adverse effects of these anti-cancer agents [ 42 , 43 , 44 ]. The primary application area of hiPSC-CM assays has focused on cardiotoxicity screening of several anti-cancer agents [ 45 , 46 , 47 , 48 , 49 , 50 ]. In the last several decades, there have been tremendous advances in anticancer drug discovery and research, with more than 100 anticancer drugs that have been approved by the FDA [ 51 , 52 , 53 ].…”

Section: Assessing Chemotherapy-induced Chronic Cardiotoxicity Using ...mentioning

confidence: 99%

Chronic Cardiotoxicity Assays Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs)

Narkar

Willard

Blinova

2022

IJMS

View full text Add to dashboard Cite

Cardiomyocytes (CMs) differentiated from human induced pluripotent stem cells (hiPSCs) are increasingly used in cardiac safety assessment, disease modeling and regenerative medicine. A vast majority of cardiotoxicity studies in the past have tested acute effects of compounds and drugs; however, these studies lack information on the morphological or physiological responses that may occur after prolonged exposure to a cardiotoxic compound. In this review, we focus on recent advances in chronic cardiotoxicity assays using hiPSC-CMs. We summarize recently published literature on hiPSC-CMs assays applied to chronic cardiotoxicity induced by anticancer agents, as well as non-cancer classes of drugs, including antibiotics, anti-hepatitis C virus (HCV) and antidiabetic drugs. We then review publications on the implementation of hiPSC-CMs-based assays to investigate the effects of non-pharmaceutical cardiotoxicants, such as environmental chemicals or chronic alcohol consumption. We also highlight studies demonstrating the chronic effects of smoking and implementation of hiPSC-CMs to perform genomic screens and metabolomics-based biomarker assay development. The acceptance and wide implementation of hiPSC-CMs-based assays for chronic cardiotoxicity assessment will require multi-site standardization of assay protocols, chronic cardiac maturity marker reproducibility, time points optimization, minimal cellular variation (commercial vs. lab reprogrammed), stringent and matched controls and close clinical setting resemblance. A comprehensive investigation of long-term repeated exposure-induced effects on both the structure and function of cardiomyocytes can provide mechanistic insights and recapitulate drug and environmental cardiotoxicity.

show abstract

Circulating high-sensitivity troponin T and microRNAs as markers of myocardial damage during childhood leukaemia treatment

Cited by 19 publications

References 39 publications

Emerging roles of microRNA‐208a in cardiology and reverse cardio‐oncology

Emerging roles of microRNA‐208a in cardiology and reverse cardio‐oncology

MicroRNA in the Diagnosis and Treatment of Doxorubicin-Induced Cardiotoxicity

Chronic Cardiotoxicity Assays Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs)

Contact Info

Product

Resources

About